Navigation Links
New drug could reduce tissue damage after heart attack

A study led by UCL (University College London) scientists has designed a new drug that inhibits the adverse effects of C reactive protein (CRP), a protein that contributes to tissue damage in heart attacks and strokes. The findings, published in the journal Nature, suggest that targeting CRP may produce both immediate and long-term clinical benefits following a heart attack.

CRP is normally present at trace levels in the blood but its concentration increases sharply in almost all diseases including trauma, infection, strokes and chronic illnesses such as rheumatoid arthritis and Crohn's disease. CRP levels also rise dramatically after a heart attack. Patients with the greatest and most persistent increases in CRP concentration suffer higher mortality, and CRP is always deposited in and around the damaged heart tissue.

Inflammation contributes significantly to the extent of heart attack damage and this can be exacerbated by CRP. The UCL team has previously shown that human CRP increases the severity of damage in experimental models of heart attack and stroke. This first identified CRP as a valid therapeutic target. The present collaborative study has now rationally designed a potent small molecule inhibitor of CRP.

The new compound, bis(phosphocholine)-hexane, is bound by CRP, inhibits all CRP functions in the test tube, and blocks the tissue damaging effect of CRP in an experimental heart attack model.

Professor Mark Pepys, of the UCL Centre for Amyloidosis and Acute Phase Proteins, whose work on CRP has been supported by the Medical Research Council since 1979, says: "Although heart attacks are responsible for about one third of all deaths in developed countries, most patients survive a first heart attack. However, if they have a large scar, patients go on to develop heart failure which is eventually fatal. Reducing the immediate damage is thus critically important.

"We had previously invented a new mechanism of drug action for small molecules bound by target proteins. Coupled with knowledge of the structure and properties of CRP, we were able to design the CRP inhibitor.

"We now propose to develop a CRP inhibitor as rapidly as possible for testing in patients with heart attacks.

"The drug would be given as soon as patients arrived in hospital. If effective, it would reduce the amount of damage in the heart, thus limiting both early mortality and the size of the scar left in the heart.

"Provided adequate support is available, it should be possible to undertake clinical trials of CRP inhibition within a couple of years. If the treatment proves safe and effective, we also aim to investigate its effectiveness in strokes.

"It is likely that CRP contributes to tissue damage in a range of diseases in which CRP levels are greatly increased, and the inhibition of CRP may thus find broad application in medicine."

Patents, patent applications and proprietary knowledge related to this work are owned by Pentraxin Therapeutics Ltd, a UCL spin out company of which Professor Pepys is director.


'"/>

Source:University College London


Related biology news :

1. Protein discovery could unlock the secret to better TB treatment
2. Tiny particles could solve billion-dollar problem
3. First atlas of key brain genes could speed research on cancer, neurological diseases
4. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
5. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
6. How the environment could be damaging mens reproductive health
7. Dead zone area in Gulf could be increasing, researchers say
8. Growth in biomass could put US on road to energy independence
9. Nano-bumps could help repair clogged blood vessels
10. Researchers develop assay that could be applied to drug screening
11. Currents could disrupt ocean food chain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Diversity focused ... annual multi-city Fueling the Growth pitch competition to uncover the top technology-driven, women-led startups ... be an integral part of each city’s entrepreneurial events going on that week – ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... molecular manufacturing and other transformative technologies, announced the winners for the 2017 Foresight ... other for Theory in nanotechnology/molecular manufacturing. , Established in 1993 and named in ...
(Date:9/19/2017)... ... 19, 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, ... book "Stem Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan met in ... an interest in the potential of stem cell therapy and a fast friendship was formed. ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... technologies, today announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell ... real-time image analysis to isolate single cells and provide visual documentation of monoclonality ...
Breaking Biology Technology: